ABNewswire - Press Release Distribution Service

Monday, March 30, 2026

Lily Allen Performs West End Girl 2026 Tickets: Best Deals with CITY10 at CapitalCityTickets.com

Catch Lily Allen Performs West End Girl live in 2026! From sold-out theater shows to new arena dates, experience her full album performance plus hits like Smile, The Fear, and Not Fair. Grab discount tickets with promo code CITY10 at CapitalCityTickets.com and don't miss this unforgettable pop event.

Lily Allen is bringing her acclaimed 2025 album West End Girl to life on the 2026 "Performs West End Girl" North American tour. After selling out spring theater shows in Chicago, Toronto, Boston, New York, and more, she's added major fall arena dates including Madison Square Garden and The Kia Forum. Secure discount Lily Allen 2026 tickets with exclusive promo code CITY10 at CapitalCityTickets.com.

Lily Allen is returning to North America in 2026 with her highly anticipated “Lily Allen Performs West End Girl” tour. The British pop icon will perform her critically acclaimed 2025 album West End Girl in its entirety, track by track, delivering a theatrical and deeply personal live experience.

Following overwhelming demand and multiple sold-out theater shows in spring, Lily Allen has added major arena dates for fall 2026. Fans can now secure discount Lily Allen 2026 tickets with exclusive promo code CITY10 at CapitalCityTickets.com for some of the best savings available.

Why See Lily Allen Performs West End Girl Live in 2026?

This tour offers a unique opportunity to hear the full West End Girl album live, alongside her biggest career-spanning hits. Known for her witty lyrics, sharp social commentary, and infectious pop-reggae-ska sound, Lily Allen’s live shows are energetic, emotional, and unforgettable.

Confirmed Lily Allen 2026 North American Tour Dates

Spring 2026 Theater Dates (many already sold out – resale tickets moving fast):

April 3, 2026 – Chicago, IL @ The Auditorium Theatre
April 4, 2026 – Chicago, IL @ The Auditorium Theatre
April 7, 2026 – Toronto, ON @ Massey Hall
April 8, 2026 – Toronto, ON @ Massey Hall
April 11, 2026 – Boston, MA @ Orpheum Theatre
April 12, 2026 – Boston, MA @ Orpheum Theatre
April 14, 2026 – New York, NY @ Radio City Music Hall
April 15, 2026 – Brooklyn, NY @ Kings Theatre
April 17, 2026 – Philadelphia, PA @ The Met
April 19, 2026 – Washington, DC @ Warner Theatre
April 21, 2026 – Atlanta, GA @ Fox Theatre
April 25, 2026 – Los Angeles, CA @ The Orpheum Theatre
April 28, 2026 – San Francisco, CA @ The Masonic

Fall 2026 Arena Dates (Newly Added – High Demand Expected):

September 3, 2026 – New York, NY @ Madison Square Garden
September 4, 2026 – Boston, MA @ MGM Music Hall at Fenway
September 6, 2026 – Philadelphia, PA @ Xfinity Mobile Arena
September 8, 2026 – Montreal, QC @ Bell Centre
September 10, 2026 – Toronto, ON @ RBC Amphitheatre (or similar arena)
September 12, 2026 – Detroit, MI @ Fox Theatre
September 13, 2026 – Chicago, IL @ United Center
September 16, 2026 – Minneapolis, MN @ The Armory
September 18, 2026 – Morrison, CO @ Red Rocks Amphitheatre
September 21, 2026 – Vancouver, BC @ Rogers Arena
September 23, 2026 – San Francisco, CA @ Chase Center
September 25, 2026 – Los Angeles, CA @ The Kia Forum

Additional dates may be announced. Check CapitalCityTickets.com for the latest updates.

How to Buy Discount Lily Allen 2026 Tickets with Promo Code CITY10

With many spring shows already sold out on primary sites, the secondary market is your best option for great seats.

CapitalCityTickets.com provides competitive pricing with a 100% buyer guarantee. Here’s how to save:

Go to CapitalCityTickets.com and search “Lily Allen”.
Choose your preferred 2026 date and seating section.
Enter promo code CITY10 at checkout to apply your discount.
Complete your secure purchase – instant or mail delivery available.

Using CITY10 helps you get better deals on Chicago, New York, Toronto, Boston, Philadelphia, and Los Angeles shows before prices rise closer to show dates.

Lily Allen Hit Singles: FAQ

Here are answers to common questions about Lily Allen’s most popular songs that fans love to hear live:

What are Lily Allen’s biggest hit singles? Her most successful and recognizable tracks include:

Smile (2006) – Her breakthrough debut single, a cheeky reggae-pop revenge anthem that topped the UK charts.
Not Fair (2009) – A witty, honest relationship song that became a massive hit.
The Fear (2009) – A sharp critique of fame and celebrity culture; reached No. 1 in the UK.
Fuck You (2009) – Her bold anti-establishment protest song that gained global attention.
LDN (2006) – A catchy yet dark portrayal of London life.
Somewhere Only We Know (2013) – Her heartfelt cover of the Keane classic that became a huge streaming success.
Other fan favorites: “Hard Out Here,” “22,” “Alfie,” and newer tracks from West End Girl like the title track and “P***y Palace.”

Will Lily Allen play her old hits on the 2026 West End Girl Tour? Yes — while the core of each show is a full performance of the West End Girl album in sequence, she is expected to include a selection of career-spanning hits in the setlist, especially on the larger arena dates.

What is the concept of the West End Girl Tour? The tour is built around performing her 2025 album West End Girl (often called her “divorce record”) from start to finish, creating a narrative, theatrical experience for fans.

Are Lily Allen 2026 concerts family-friendly? Her music contains strong language and mature themes. Most venues are all-ages, but parental discretion is advised, especially for younger children.

When do Lily Allen 2026 tickets usually sell out? Spring theater dates have already seen many sell-outs. Fall arena shows are expected to move quickly, especially Madison Square Garden, Red Rocks, and The Kia Forum.

Don’t miss your chance to see Lily Allen live in 2026! Grab discount Lily Allen Performs West End Girl tickets today with promo code CITY10 at CapitalCityTickets.com and secure your seats for what promises to be one of the most talked-about pop tours of the year.

Tickets subject to availability. Prices vary by date and section. CapitalCityTickets.com is an independent resale marketplace and not affiliated with the artist or primary ticketing companies.

Media Contact
Company Name: CapitalCityTickets.com
Contact Person: Media Relations
Email:Send Email
Phone: 1-855-514-5624
Country: United States
Website: https://www.capitalcitytickets.com/Lily-Allen-Tickets

Stargardt Disease Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Stargardt Disease pipeline constitutes 20+ key companies continuously working towards developing 20+ Stargardt Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Stargardt Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Stargardt Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Stargardt Disease Market.

Get a Free Sample PDF Report to know more about Stargardt Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/stargardt-disease-stgd-pipeline-insight

Some of the key takeaways from the Stargardt Disease Pipeline Report:

Companies across the globe are diligently working toward developing novel Stargardt Disease treatment therapies with a considerable amount of success over the years.
Stargardt Disease companies working in the treatment market are Ocugen, Belite Bio, Inc, Alkeus Pharmaceuticals, Biophytis, reVision Therapeutics, Inc, IVERIC bio, Inc., Nanoscope Therapeutics, Belite Bio, Kubota Vision, and others, are developing therapies for the Stargardt Disease treatment

Emerging Stargardt Disease therapies in the different phases of clinical trials are- OCU410ST, Tinlarebant, ALK-001, BIO-201, REV-0100, Avacincaptad pegol, MCO-010, LBS-008, Emixustat, and others are expected to have a significant impact on the Stargardt Disease market in the coming years.
In March 2026, VeonGen Therapeutics, a clinical-stage genetic medicine company focused on developing next-generation gene therapies, has announced clinical progress for VG801, which will be presented in an oral session at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, scheduled for May 3–7 in Denver, Colorado. VG801 is an investigational gene therapy targeting ABCA4-associated retinal diseases, including Stargardt disease, and is currently being evaluated in an ongoing Phase 1/2 first-in-human clinical trial (NCT07002398) assessing safety, tolerability, and early efficacy. Both adult and pediatric patients have received the treatment, with nine completing six-month follow-up and some reaching twelve months. To date, VG801 has demonstrated a favorable safety profile, with no dose-limiting toxicities or serious adverse events reported.
In March 2026, Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for degenerative retinal diseases with significant unmet needs, announced its preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with a business update. The company noted that 2025 was a milestone year, highlighted by positive topline results from its pivotal Phase 3 DRAGON trial, positioning tinlarebant as a potential first-in-class therapy for Stargardt disease.
In January 2026, Ocugen, Inc. reported encouraging outcomes from its Phase 1 GARDian1 study of OCU410ST, an innovative gene therapy being developed for Stargardt disease, published in Nature Eye. The study showed a favorable safety and tolerability profile, along with meaningful clinical benefits over a 12-month period. Notably, treated patients experienced a 54% reduction in atrophic lesion progression and improvements in visual acuity. Unlike mutation-specific approaches, OCU410ST is designed to alter the underlying disease course, positioning it as a potentially transformative option for the more than 100,000 individuals affected across the U.S. and Europe, where no approved therapies currently exist. Meanwhile, the Phase 2/3 GARDian3 trial is progressing ahead of plan, with a Biologics License Application (BLA) submission targeted for 2027.
In December 2025, A Phase 3 study evaluating Belite Bio’s tinlarebant in adolescents with a rare inherited eye disorder successfully achieved its primary endpoint, prompting the company to expand its regulatory strategy to include the United States, alongside other planned filings next year. The trial enrolled 104 patients with Stargardt disease type 1 (STGD1), who were randomly assigned to receive either tinlarebant or a placebo. STGD1 is characterized by progressive retinal lesions and loss of central vision. Tinlarebant is an oral investigational therapy designed to limit the buildup of vitamin A–derived toxic byproducts believed to be a key driver of disease progression in STGD1.
In June 2025, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company at the forefront of gene therapies for vision-related diseases, has announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) amendment to launch a Phase 2/3 pivotal confirmatory trial of OCU410ST. This modifier gene therapy candidate is being developed to treat all forms of Stargardt disease (ABCA4-associated retinopathies). OCU410ST has already received both Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA for the treatment of ABCA4-related conditions, including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.
In March 2025, Barcelona-based genetic medicines company, SpliceBio, has administered the first dose in the Phase 1/2 ASTRA clinical trial (NCT identifier pending) evaluating SB-007, a dual adeno-associated virus (AAV) vector-based gene therapy for Stargardt disease. This inherited retinal disorder, caused by mutations in the ABCA4 gene, leads to progressive vision loss and currently has no approved treatments. Affecting approximately 1 in 8,000 to 10,000 people, it is the most common form of inherited juvenile macular degeneration.
In February 2025, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for blindness diseases, has secured alignment with the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2/3 pivotal confirmatory trial for OCU410ST. If the trial yields positive results, it could serve as the foundation for a biologics license application (BLA) submission.
In January 2025, Alkeus Pharmaceuticals, Inc., a biopharmaceutical company focused on retinal disease treatment, has reported positive interim results from its TEASE-3 study. The data indicate that early-stage Stargardt disease patients receiving oral gildeuretinol acetate exhibited no disease progression and maintained stable visual acuity over multiple years.
In September 2024, Nanoscope Therapeutics Inc., a clinical-stage biotechnology firm focused on gene therapies for retinal degenerative diseases and age-related macular degeneration (AMD), announced a successful End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The meeting focused on the clinical program assessing MCO-010 for treating severe vision loss caused by Stargardt Macular Degeneration (SMD), paving the way for the progression of MCO-010 to a Phase 3 registrational trial.
In May 2024, Alkeus Pharmaceuticals, Inc. has revealed that additional favorable findings from its TEASE-3 clinical trial investigating gildeuretinol in adolescent and young-adult patients with early-stage Stargardt disease will be disclosed at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting.
In April 2024, The Data Safety and Monitoring Board (DSMB) has approved advancement to the medium dose in Ocugen's OCU410ST clinical trial for Stargardt disease. This decision comes after confirming the safety and tolerability of the low dose of modifier gene therapy OCU410ST, representing a notable progression in the trial's dose-escalation phase. Ocugen has disclosed that three patients have received the low dose in the Phase I/II clinical trial for Stargardt disease

Stargardt Disease Overview

Stargardt Disease is a rare genetic eye disorder that causes progressive vision loss due to the degeneration of the macula, the central part of the retina. It is the most common form of inherited juvenile macular degeneration and is primarily caused by mutations in the ABCA4 gene. Symptoms typically appear in childhood or adolescence and include blurred vision, difficulty seeing in low light, and central vision loss. There is currently no cure, but research into gene therapy and other treatments is ongoing.

Explore the latest Stargardt Disease pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Stargardt Disease Clinical Trials

Emerging Stargardt Disease Drugs Under Different Phases of Clinical Development Include:

OCU410ST: Ocugen
Tinlarebant: Belite Bio, Inc
ALK-001: Alkeus Pharmaceuticals
BIO-201: Biophytis
REV-0100: reVision Therapeutics, Inc
Avacincaptad pegol: IVERIC bio, Inc.
MCO-010: Nanoscope Therapeutics
LBS-008: Belite Bio
Emixustat: Kubota Vision

Stargardt Disease Route of Administration

Stargardt Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Stargardt Disease Molecule Type

Stargardt Disease Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Stargardt Disease Pipeline Therapeutics Assessment

Stargardt Disease Assessment by Product Type
Stargardt Disease By Stage and Product Type
Stargardt Disease Assessment by Route of Administration
Stargardt Disease By Stage and Route of Administration
Stargardt Disease Assessment by Molecule Type
Stargardt Disease by Stage and Molecule Type

DelveInsight's Stargardt Disease Report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Stargardt Disease product details are provided in the report. Download the Stargardt Disease pipeline report to learn more about the emerging Stargardt Disease therapies

Some of the key companies in the Stargardt Disease Therapeutics Market include:

Key companies developing therapies for Stargardt Disease are - Astellas Pharma, Spark Therapeutics, ReVision Therapeutics, and others.

Stargardt Disease Pipeline Analysis:

The Stargardt Disease pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Stargardt Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Stargardt Disease Treatment.
Stargardt Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Stargardt Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Stargardt Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Stargardt Disease drugs and therapies

Stargardt Disease Pipeline Market Drivers

Increased Research and Development Activities, new and developed robust Pipeline are some of the important factors that are fueling the Stargardt Disease Market.

Stargardt Disease Pipeline Market Barriers

However, complications with available treatment options, lack of Disease Awareness, poor mechanism understanding for accurately predicting disease progression and other factors are creating obstacles in the Stargardt Disease Market growth.

Scope of Stargardt Disease Pipeline Drug Insight

Coverage: Global
Key Stargardt Disease Companies: Ocugen, Belite Bio, Inc, Alkeus Pharmaceuticals, Biophytis, reVision Therapeutics, Inc, IVERIC bio, Inc., Nanoscope Therapeutics, Belite Bio, Kubota Vision, and others
Key Stargardt Disease Therapies: OCU410ST, Tinlarebant, ALK-001, BIO-201, REV-0100, Avacincaptad pegol, MCO-010, LBS-008, Emixustat, and others
Stargardt Disease Therapeutic Assessment: Stargardt Disease current marketed and Stargardt Disease emerging therapies
Stargardt Disease Market Dynamics: Stargardt Disease market drivers and Stargardt Disease market barriers

Request for Sample PDF Report for Stargardt Disease Pipeline Assessment and clinical trials

Table of Contents

1. Stargardt Disease Report Introduction

2. Stargardt Disease Executive Summary

3. Stargardt Disease Overview

4. Stargardt Disease- Analytical Perspective In-depth Commercial Assessment

5. Stargardt Disease Pipeline Therapeutics

6. Stargardt Disease Late Stage Products (Phase II/III)

7. Stargardt Disease Mid Stage Products (Phase II)

8. Stargardt Disease Early Stage Products (Phase I)

9. Stargardt Disease Preclinical Stage Products

10. Stargardt Disease Therapeutics Assessment

11. Stargardt Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Stargardt Disease Key Companies

14. Stargardt Disease Key Products

15. Stargardt Disease Unmet Needs

16 . Stargardt Disease Market Drivers and Barriers

17. Stargardt Disease Future Perspectives and Conclusion

18. Stargardt Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Tyler Childers 2026 Concert Tickets On Sale Now - Save with CITY10 at CapitalCityTickets.com

Experience the soulful storytelling and high-energy live show of Tyler Childers on his 2026 Snipe Hunt Tour. Grab affordable tickets with promo code CITY10 at CapitalCityTickets.com and sing along to hits like Feathered Indians, All Your'n, and Lady May in venues across the country.

Tyler Childers is bringing his raw Appalachian sound to the road in 2026 with the Snipe Hunt Tour, supporting his 2025 album Snipe Hunter. Tickets are on sale now for major stops including Dallas (Dos Equis Pavilion), Chicago (Wrigley Field), Hersheypark Stadium, Birmingham, and more. Get cheap Tyler Childers 2026 concert tickets with exclusive promo code CITY10 at CapitalCityTickets.com.

Tyler Childers, the Grammy-nominated Kentucky singer-songwriter known for his raw Appalachian sound and heartfelt storytelling, is hitting the road in 2026 with his highly anticipated Snipe Hunt Tour. Supporting his 2025 album Snipe Hunter, the tour features a mix of intimate amphitheater shows, major stadium stops (including Chicago’s Wrigley Field), and festival appearances across North America and Europe.

Fans are already scrambling for tickets as demand surges for Childers’ signature blend of country, folk, and bluegrass. The good news? You can grab cheap Tyler Childers 2026 concert tickets right now with a special promo code CITY10 at CapitalCityTickets.com — helping you save on every order while securing great seats before prices climb higher.

Why See Tyler Childers Live in 2026?

Childers delivers electrifying live performances with his band The Food Stamps, blending high-energy honky-tonk anthems with soulful ballads. The Snipe Hunt Tour promises unforgettable nights filled with fan favorites and new material from Snipe Hunter. Whether you’re a longtime follower or discovering his music for the first time, these shows deliver pure, authentic country emotion.

Full List of Tyler Childers 2026 Snipe Hunt Tour Dates

Here are the confirmed North American dates (European leg runs in March 2026). Additional dates and special guests (including Jon Batiste, Wednesday, Evan Honer, Scott T. Smith, and others at select stops) may be added:

April 23, 2026 – Dallas, TX @ Dos Equis Pavilion (with Robert Earl Keen & Scott T. Smith)
June 4, 2026 – Birmingham, AL @ Coca-Cola Amphitheater
June 10, 2026 – Darien Center, NY @ Darien Lake Amphitheater
June 11, 2026 – Hershey, PA @ Hersheypark Stadium
July 9, 2026 – St. Louis, MO @ Hollywood Casino Amphitheater
July 12, 2026 – Chicago, IL @ Wrigley Field
July 14, 2026 – Kansas City, MO @ Morton Amphitheater
July 15, 2026 – Des Moines, IA @ Casey’s Center
September 30, 2026 – Sacramento, CA @ Golden 1 Center
October 2, 2026 – Seattle, WA @ Climate Pledge Arena
October 3, 2026 – Portland, OR @ Moda Center

(Note: Some dates include festival appearances like Railbird Festival or Buckeye Country Superfest. Always check the venue or CapitalCityTickets.com for the latest updates and special guests.)

How to Buy Cheap Tyler Childers 2026 Tickets with Promo Code CITY10

Tickets are on sale now, and prices can rise quickly as shows approach — especially for premium venues like Wrigley Field and Dos Equis Pavilion.

CapitalCityTickets.com offers some of the most competitive prices on the secondary market with 100% buyer guarantees. Here’s how to save even more:

Visit CapitalCityTickets.com and search for “Tyler Childers”.
Select your preferred 2026 show date and best available seats.
At checkout, enter promo code CITY10 to activate your discount.
Complete your secure purchase — tickets are delivered instantly or via mail.

Using CITY10 can help lower your total cost compared to face-value or other resale sites. Act fast — popular dates in Dallas, Chicago, and Hershey are expected to sell out quickly.

Tyler Childers Hit Singles: FAQ

Here are answers to common questions about Tyler Childers’ most popular songs that fans love hearing live:

What are Tyler Childers’ biggest hit singles? His most streamed and fan-favorite tracks include:

Feathered Indians – A tender, acoustic love song that became a breakout hit and fan anthem.
All Your’n – A heartfelt ode to home and love; one of his most commercially successful singles with massive streaming numbers.
Lady May – A beautiful, poetic ballad dedicated to his wife, often considered one of his finest songwriting moments.
In Your Love – The Grammy-nominated lead single from Rustin’ in the Rain, known for its powerful video and emotional depth.
Whitehouse Road – A rowdy, storytelling favorite that captures his early raw energy.
Shake the Frost (Live) – A live staple that showcases his incredible vocal range and stage presence.
Other standouts: “House Fire,” “Nose on the Grindstone,” and newer tracks like “Oneida” from Snipe Hunter.

Which Tyler Childers songs will he likely play on the 2026 Snipe Hunt Tour? Expect a mix of classics (“Feathered Indians,” “All Your’n,” “Lady May”) plus deep cuts and material from Snipe Hunter. Childers’ setlists often vary, giving fans a fresh experience each night.

Does Tyler Childers have any new music for the 2026 tour? Yes — the tour supports Snipe Hunter (released in 2025), so you’ll hear several new songs alongside the hits that made him a roots-music superstar.

Is Tyler Childers family-friendly? His music is generally suitable for older teens and adults due to occasional strong language and mature themes, but the energy at his shows is communal and welcoming.

Are there any age restrictions for Tyler Childers 2026 concerts? Most venues are all-ages, but some amphitheaters have restrictions for GA pit or lawn areas. Check the specific venue policy when purchasing tickets.

Ready to experience Tyler Childers live? Don’t wait — Tyler Childers 2026 concert tickets are moving fast. Head over to CapitalCityTickets.com today, apply promo code CITY10, and lock in your seats for what promises to be one of the best country tours of the year.

Tickets are subject to availability. Prices may vary by show and seating. CapitalCityTickets.com is an independent resale marketplace and not affiliated with the artist or primary ticketing companies.

Celiac Disease Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Celiac Disease pipeline constitutes 25+ key companies continuously working towards developing 30+ Celiac Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Celiac Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Celiac Disease Market.

The Celiac Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Celiac Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/celiac-disease-pipeline-insight

Some of the key takeaways from the Celiac Disease Pipeline Report:

Companies across the globe are diligently working toward developing novel Celiac Disease treatment therapies with a considerable amount of success over the years.
Celiac Disease companies working in the treatment market are Takeda, AnokionSA, Mozart Therapeutics, AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others, are developing therapies for the Celiac Disease treatment

Emerging Celiac Disease therapies in the different phases of clinical trials are- TAK-062, KAN-101, MTX 101, AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others are expected to have a significant impact on the Celiac Disease market in the coming years.
In June 2025, Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company specializing in autoimmune and related disorders, has reported positive results from a Phase 1b trial of its lead candidate, FB102 (study FB102-101), in celiac disease.
In May 2025, Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug TEV-53408, an anti-IL-15 antibody, for the treatment of celiac disease in patients adhering to a gluten-free diet. TEV-53408 is currently undergoing evaluation in a Phase 2a clinical trial to determine its safety and effectiveness in adults with celiac disease. The FDA's Fast Track program aims to speed up the development and review of therapies for serious conditions with significant unmet medical needs.
In March 2025, Barinthus Biotherapeutics plc (NASDAQ: BRNS) has entered 2025 with a renewed strategic focus on immunological and inflammatory diseases. Following its restructuring, the company is well-positioned to advance its lead asset, VTP-1000, along with the SNAP-TI platform, for the treatment of celiac disease. With innovative design features that enhance antigen targeting, allow intramuscular administration, and potentially improve tolerability, VTP-1000 has the potential to become a leading therapy for the approximately 80 million people worldwide affected by celiac disease.
In February 2025, PhaseV, a leader in software and machine learning (ML) for clinical trial optimization, announced a strategic partnership with Alimentiv Inc., a global gastrointestinal (GI) contract research organization (CRO). This collaboration aims to enhance the design and execution of advanced adaptive clinical trials for various GI conditions, including inflammatory bowel disease (IBD), celiac disease, eosinophilic gastrointestinal disease (EGID), and other related disorders.
In October 2024, Topas Therapeutics reported promising topline results from its Phase IIa trial of TPM502 in celiac disease patients. The findings provide the first clinical proof of concept for the company's proprietary nanoparticle platform, highlighting its potential to induce targeted, antigen-specific tolerogenic effects.
In September 2024, Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies that direct T cells to combat disease, has commenced its first-in-human Phase I trial of VTP-1000 in adults with celiac disease.

Celiac Disease Overview

The World Gastroenterology Organization (WGO) defines celiac disease, also referred to as gluten-sensitive enteropathy, non-tropical sprue, or coeliac disease/sprue, as a chronic, multiple-organ small intestinal immune-mediated enteropathy that is precipitated in genetically predisposed individuals by exposure to dietary gluten.

Explore the latest Celiac Disease pipeline insights for 2025 and stay ahead in market trends and Celiac Disease emerging therapies

Emerging Celiac Disease Drugs Under Different Phases of Clinical Development Include:

TAK-062: Takeda
KAN-101: AnokionSA
MTX 101: Mozart Therapeutics
AMY02: AMYRA Biotech AG
EQ102: Equillium Bio.
DONQ52: Chugai Pharmaceutical Co., Ltd.
CALY-002: Calypso Biotech
Latiglutenase: ImmunogenX, Inc.
Ordesekimab: Amgen Inc.

Celiac Disease Route of Administration

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Celiac Disease Molecule Type

Celiac Disease Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Celiac Disease Pipeline Therapeutics Assessment

Celiac Disease Assessment by Product Type
Celiac Disease By Stage and Product Type
Celiac Disease Assessment by Route of Administration
Celiac Disease By Stage and Route of Administration
Celiac Disease Assessment by Molecule Type
Celiac Disease by Stage and Molecule Type

DelveInsight's Celiac Disease Report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Celiac Disease product details are provided in the report. Download the Celiac Disease pipeline report to learn more about the emerging Celiac Disease therapies

Some of the key companies in the Celiac Disease Therapeutics Market include:

Key companies developing therapies for Celiac Disease are - Takeda Pharmaceutical Co Ltd, Amyra Biotech AG, Topas Therapeutics GmbH, Zedira GmbH, 9 Meters Biopharma Inc, Ahead Therapeutics SL, Allero Therapeutics BV, Amgen Inc, Anokion SA, AnTolRx Inc, Calypso Biotech SA., and others.

Celiac Disease Pipeline Analysis:

The Celiac Disease pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Celiac Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Celiac Disease Treatment.
Celiac Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Celiac Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Celiac Disease market.

Download Sample PDF Report to know more about Celiac Disease drugs and therapies

Celiac Disease Pipeline Market Drivers

Increasing prevalence of Celiac Disease, increasing R&D activities, No Approved Therapy are some of the important factors that are fueling the Celiac Disease Market.

Celiac Disease Pipeline Market Barriers

However, limited patient awareness about the disease, poor Patient Compliance and other factors are creating obstacles in the Celiac Disease Market growth.

Scope of Celiac Disease Pipeline Drug Insight

Coverage: Global
Key Celiac Disease Companies: Takeda, AnokionSA, Mozart Therapeutics, AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others
Key Celiac Disease Therapies: TAK-062, KAN-101, MTX 101, AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others
Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers

Request for Sample PDF Report for Celiac Disease Pipeline Assessment and clinical trials

Table of Contents

1. Celiac Disease Report Introduction

2. Celiac Disease Executive Summary

3. Celiac Disease Overview

4. Celiac Disease- Analytical Perspective In-depth Commercial Assessment

5. Celiac Disease Pipeline Therapeutics

6. Celiac Disease Late Stage Products (Phase II/III)

7. Celiac Disease Mid Stage Products (Phase II)

8. Celiac Disease Early Stage Products (Phase I)

9. Celiac Disease Preclinical Stage Products

10. Celiac Disease Therapeutics Assessment

11. Celiac Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Celiac Disease Key Companies

14. Celiac Disease Key Products

15. Celiac Disease Unmet Needs

16 . Celiac Disease Market Drivers and Barriers

17. Celiac Disease Future Perspectives and Conclusion

18. Celiac Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

TECHSPO Chicago 2026 Unites Business, Tech and Marketing Leaders for High-Impact Expo

Chicago, IL - TECHSPO Chicago Technology Expo returns May 19-20, 2026, to the Soldier Field Stadium, uniting business leaders, technologists, marketers, and innovators for a high-impact, two-day showcase of next-generation digital technology.

Part of the globally recognized TECHSPO Event Series, TECHSPO Chicago 2026 will feature cutting-edge Internet, Mobile, AdTech, MarTech, and SaaS innovations, offering attendees hands-on access to the tools and platforms shaping the future of digital business worldwide.

Designed for professionals who demand results, TECHSPO Chicago delivers a fast-paced, experiential expo floor featuring live technology demonstrations, product launches, and direct engagement with solution providers driving transformation across industries.

“TECHSPO Chicago is where global innovation turns into real-world execution. This event delivers businesses direct access to the technologies, ideas, and high-value connections they need to accelerate growth, compete smarter, and stay ahead in an increasingly fast-moving digital economy.”

A key differentiator of TECHSPO Chicago is its co-location with DigiMarCon Chicago, a limited-attendance Digital Marketing, Media & Advertising Conference held alongside the expo. Together, the events create a powerful two-in-one experience, blending strategic education and inspiration with hands-on technology discovery and networking.

By bringing TECHSPO and DigiMarCon together, attendees gain unmatched value — strategy, innovation, and execution all under one roof, it’s a global-caliber experience built for today’s digital leaders.”

TECHSPO Chicago 2026 is expected to attract attendees and exhibitors from across America and international markets, reinforcing Chicago as a hub for technology, creativity, and innovation.

Registration is now openFor event details and passes, visit https://techspochicago.com/.

About TECHSPO Technology Expo

TECHSPO Technology Expo is a global technology event series held in major cities across North America, Europe, Asia-Pacific, and beyond. TECHSPO events bring together technology providers, brands, innovators, and professionals to showcase the latest advancements in Internet, Mobile, AdTech, MarTech, SaaS, and emerging technologies.

Known for its hands-on format and high-quality networking, TECHSPO enables attendees to see, test, and experience technologies while connecting directly with the companies and leaders driving digital transformation worldwide. The TECHSPO Event Series continues to serve as a trusted global platform for innovation, education, and business growth.

For more information on TECHSPO events worldwide, visit https://techspo.co/events/

Media Contact
Company Name: TECHSPO, LLC.
Email:Send Email
Phone: +1 (800) 805-5385
Address:406 Broadway, Suite 217
City: Santa Monica
State: CA
Country: United States
Website: https://techspo.co

Projecting the Global Blood Flow Measurement Devices Market Size to Expand at a 6.19% CAGR Through 2032, DelveInsight Analysis

Blood Flow Measurement Devices Market Insights, Competitive Landscape, and Market Forecast - 2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers.

As per DelveInsight’s assessment, The blood flow measurement devices market is primarily driven by the increasing prevalence of cardiovascular diseases, diabetes, and related risk factors. Growth is further supported by advancements in device technology, the expanding adoption of minimally invasive and point-of-care diagnostic solutions, and rising product development initiatives by key market players.

DelveInsight's “Blood Flow Measurement Devices Market Insights, Competitive Landscape, and Market Forecast - 2032” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Blood Flow Measurement Devices companies actively working in the market.

Explore the future of healthcare innovation with our comprehensive Blood Flow Measurement Devices Market Forecast. Stay ahead in the industry!

https://www.delveinsight.com/report-store/blood-flow-measurement-devices-market

Blood Flow Measurement Devices Overview

Blood flow measurement devices are medical instruments used to assess and monitor the rate and volume of blood circulation within vessels. These devices are essential in diagnosing and managing cardiovascular conditions, peripheral artery disease, and critical care scenarios.

Common types include Doppler ultrasound devices, laser Doppler flowmeters, electromagnetic flowmeters, and thermal dilution systems. Doppler-based devices are widely used due to their non-invasive nature, while invasive techniques are often employed in surgical or intensive care settings for precise measurements.

Blood Flow Measurement Devices Market Insights

The blood flow measurement devices market is primarily driven by the increasing prevalence of cardiovascular diseases, diabetes, and associated risk factors, which are boosting the demand for advanced diagnostic solutions. Continuous technological advancements such as the integration of Doppler ultrasound, laser-based technologies, and wearable sensors are improving diagnostic precision and accessibility. The growing adoption of minimally invasive and point-of-care diagnostic approaches is further supporting market expansion by enabling quicker and more convenient patient monitoring. Moreover, ongoing product development efforts and strategic investments by key players are broadening the range of innovative solutions, encouraging wider clinical and consumer adoption.

DelveInsight Analysis: The global blood flow measurement devices market size is projected to grow steadily from USD 544.01 million in 2024 to USD 874.80 million by 2032, registering a CAGR of 6.19% during the forecast period from 2025 to 2032.

To know more about why North America is leading the market growth in the Blood Flow Measurement Devices market, get a snapshot of the report Blood Flow Measurement Devices Market Trends

Recent Developments in the Blood Flow Measurement Devices Market Report

In February 2025, Beats launched the Powerbeats Pro 2, featuring advanced heart rate monitoring with LED optical sensors that measure blood flow over 100 times per second, providing precise tracking of circulation.
In January 2025, electronRx, a digital medicine company, unveiled purpleDx, a cardiopulmonary assessment that uses the iPhone camera to capture and measure blood flow around the face.
In January 2025, Lumia Health launched a wearable that tracks blood flow to the head. The Lumia™ device is designed to help users monitor and manage symptoms such as dizziness, brain fog, fatigue, and fainting. In July 2024, Flosonics Medical introduced FloPatch, a wireless, wearable Doppler device adopted by Sutter Health to monitor blood flow in critically ill patients. In June 2023, U.S.-based digital health company STAT Health launched the world’s smallest 24/7 in-ear wearable, designed to measure blood flow to the head. In June 2023, STAT Health, a U.S.-based digital health company, launched a 24/7 in-ear wearable that continuously monitors blood flow to the head. This compact device aims to help diagnose and manage symptoms like dizziness, brain fog, and fatigue, which are often linked to conditions such as long COVID, postural orthostatic tachycardia syndrome, and chronic fatigue syndrome.

Key Players in the Blood Flow Measurement Devices Market

Some of the key market players operating in the Blood Flow Measurement Devices market include- Cook, Medistim, Compumedics Limited, Permed AB, Deltex Medical Limited, Koninklijke Philips N.V., Getinge, Arjo, ATYS Medical, Moor Instruments Limited, Medtronic, AKW Medical, Inc., D. E. Hokanson, Inc., ELCAT GmbH, Oxford Optronix, QT Medical Inc., Transonic, Carolina Medical Electronics, ADINSTRUMENTS, STAT Health Informatics, Inc., and others.

To read more about the latest highlights related to Blood Flow Measurement Devices, get a snapshot of the key highlights entailed in the Blood Flow Measurement Devices Market Forecast Report

Market Analysis on the Blood Flow Measurement Devices Market

According to estimates, North America is expected to lead the blood flow measurement devices market in 2024, accounting for approximately 41% of the total share. This dominance is driven by the high incidence of cardiovascular and metabolic diseases, a well-developed healthcare infrastructure, and a strong tendency to adopt advanced medical technologies. The region also benefits from supportive reimbursement policies and an early adoption culture for innovative solutions. Additionally, the rising number of minimally invasive procedures, ongoing product launches, and increasing awareness of preventive diagnostics are likely to further strengthen North America’s position in the global market.

The competitive landscape of the blood flow measurement devices market features a combination of established multinational medical device companies and emerging innovative startups, resulting in a moderately concentrated market. Leading players such as GE Healthcare, Philips, Siemens Healthineers, Flosonics Medical, Boston Scientific, and LivaNova hold a strong position with extensive portfolios that include Doppler ultrasound systems, laser-based flowmeters, advanced imaging devices, and wearable monitoring solutions. These companies utilize robust R&D capabilities, strategic collaborations, mergers and acquisitions, and global distribution networks to strengthen their market presence and maintain a competitive advantage.

Meanwhile, emerging startups are contributing to market growth by developing wearable, wireless, and AI-enabled blood flow measurement technologies. These niche innovations, particularly for point-of-care and home monitoring applications, are fostering technological advancement and expanding the range of available solutions.

Scope of the Blood Flow Measurement Devices Market Report

Coverage: Global
Study Period: 2022–2032
Blood Flow Measurement Devices Market Segmentation By Product Type: Ultrasound-Based Devices [Doppler Ultrasound Systems and Transit-Time Flow Meters] and Laser-Based Devices [Laser Doppler Blood Flowmeters, Laser Doppler Imaging, and Laser Speckle Contrast Imaging]
Blood Flow Measurement Devices Market Segmentation By Modality: Invasive and Non-Invasive
Blood Flow Measurement Devices Market Segmentation By End Users: Hospitals and Clinics, Ambulatory Surgical Centers (ASCs), and others
Blood Flow Measurement Devices Market Segmentation By Geography: Hospitals and Clinics, Diagnostic Labs, Blood Banks, and others
Key Blood Flow Measurement Devices Companies: Cook, Medistim, Compumedics Limited, Permed AB, Deltex Medical Limited, Koninklijke Philips N.V., Getinge, Arjo, ATYS Medical, Moor Instruments Limited, Medtronic, AKW Medical, Inc., D. E. Hokanson, Inc., ELCAT GmbH, Oxford Optronix, QT Medical Inc., Transonic, Carolina Medical Electronics, ADINSTRUMENTS, STAT Health Informatics, Inc., and others
Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the Blood Flow Measurement Devices market are set to emerge as the trendsetter explore @ Blood Flow Measurement Devices Manufacturer

Table of Contents

1	Blood Flow Measurement Devices Market Report Introduction
2	Blood Flow Measurement Devices Market Executive summary
3	Regulatory and Patent Analysis
4	Blood Flow Measurement Devices Market Key Factors Analysis
5	Porter’s Five Forces Analysis
6	COVID-19 Impact Analysis on Blood Flow Measurement Devices Market
7	Blood Flow Measurement Devices Market Layout
8	Global Company Share Analysis – Key 3-5 Companies
9	Company and Product Profiles
10	Blood Flow Measurement Devices Market Drivers
11.	Blood Flow Measurement Devices Market Barriers
12.	Project Approach
13.	About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Spinal Cord Injury Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development, Kessler

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinal Cord Injury pipeline constitutes 25+ key companies continuously working towards developing 30+ Spinal Cord Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Spinal Cord Injury Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Cord Injury Market.

The Spinal Cord Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Spinal Cord Injury Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/spinal-cord-injury-pipeline-insight

Some of the key takeaways from the Spinal Cord Injury Pipeline Report:

Companies across the globe are diligently working toward developing novel Spinal Cord Injury treatment therapies with a considerable amount of success over the years.
Spinal Cord Injury companies working in the treatment market are Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, NervGen Pharma, StemCyte, Inc., and others, are developing therapies for the Spinal Cord Injury treatment

Emerging Spinal Cord Injury therapies in the different phases of clinical trials are- Allogeneic stem cell therapy, OLT1177, ALMB0166, AXER-204, FAB117-HC, AST-OPC1, Elezanumab, MT 3921, PMZ-1620, ES 135, KP-100IT, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, and others are expected to have a significant impact on the Spinal Cord Injury market in the coming years.
In March 2026, NervGen Pharma Corp., a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapies for spinal cord injury and other neurologic conditions, has announced the appointment of Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President (SVP) of Patient Advocacy and Clinical Affairs.
In November 2025, Precision Neuroscience’s wireless brain-computer interface, designed to restore function in people with paralysis, received support from SCI Ventures, a fund backed by the Christopher & Dana Reeve Foundation and other leading spinal cord injury organizations. The partnership provides Precision with access to SCI Ventures’ extensive network of patients, clinicians, and regulatory experts, helping accelerate the development and delivery of the device for individuals with spinal cord injuries and neurological conditions such as ALS and stroke.
In June 2025, Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotech company focused on developing innovative allogeneic (“off-the-shelf”) cell therapies for severe neurological and ophthalmic disorders, announced the addition of new presenters for the 3rd Annual Spinal Cord Injury Investor Symposium (3rd SCIIS). This year’s event will be entirely virtual, featuring interactive and on-demand sessions beginning on June 27, 2025.
In March 2025, Cellino and Matricelf (TASE: MTLF) announced a partnership aimed at advancing the global biomanufacturing of personalized spinal cord injury therapies. This collaboration integrates Cellino’s Nebula™ technology with Matricelf’s innovative regenerative medicine approach. By combining Cellino’s automated production of induced pluripotent stem cells (iPSCs) with Matricelf’s double autologous 3D differentiation process, the partnership seeks to enable scalable and patient-specific regenerative treatments. Cellino’s Nebula™, a proprietary closed-cassette biomanufacturing platform, is specifically designed to generate high-quality iPSCs with exceptional consistency and sterility at a large scale.
In March 2025, NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) announced the successful completion of a key preclinical study supporting its upcoming Investigational New Drug (IND) application. This study marks a significant step toward the company’s first-in-human trials. The results demonstrated that ExoPTEN treatment, across various dosing regimens, promoted motor function recovery and notably enhanced blood flow at the spinal cord injury site both critical factors for tissue repair and functional improvement.
In February 2025, Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotech company developing allogeneic cell therapies for severe neurological disorders, announced the launch of its DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. This study aims to assess the safety and performance of the Manual Inject Parenchymal Spinal Delivery System (MI PSD System), a new device designed to precisely deliver OPC1, an investigational allogeneic stem cell-based therapy, directly to the spinal cord injury site. OPC1 consists of oligodendrocyte progenitor cells and other related glial cells intended to promote spinal cord repair.
In February 2025, A pilot clinical trial suggests that spinal cord stimulation (SCS) may help reactivate dormant motor neurons and enhance leg muscle strength in individuals with spinal muscular atrophy (SMA). Researchers from the University of Pittsburgh School of Medicine conducted the study (NCT05430113), utilizing Medtronic’s Vectris SureScan device in three SMA patients. After three months of treatment, all participants showed an improvement of at least 20 meters in the six-minute walk test (6MWT), an indicator used to assess muscle endurance and fatigue.

Spinal Cord Injury Overview

Spinal Cord Injury (SCI) is damage to the spinal cord that results in partial or complete loss of motor, sensory, and autonomic functions below the level of injury. It can occur due to trauma, such as accidents or falls, or from diseases affecting the spinal cord. SCI often leads to paralysis, loss of sensation, and other complications, with the severity depending on the location and extent of the injury. Early medical intervention and rehabilitation are critical for improving outcomes.

Explore the latest Spinal Cord Injury pipeline insights for 2025 and stay ahead in market trends and Spinal Cord Injury emerging therapies

Emerging Spinal Cord Injury Drugs Under Different Phases of Clinical Development Include:

Allogeneic stem cell therapy: Athersys
OLT1177: Olatec Therapeutics
ALMB0166: AlaMab therapeutics
AXER-204: ReNetX Bio
FAB117-HC: Histocell
AST-OPC1: Lineage Cell Therapeutics
Elezanumab: AbbVie
MT 3921: Mitsubishi Tanabe Pharma
PMZ-1620: Pharmazz
ES 135: Eusol Biotech
KP-100IT: Kringle Pharma
NVG-291: NervGen Pharma
Romosozumab: VA Office of Research and Development/Kessler Institute for Rehabilitation
Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc

Spinal Cord Injury Route of Administration

Spinal Cord Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Spinal Cord Injury Molecule Type

Spinal Cord Injury Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Spinal Cord Injury Pipeline Therapeutics Assessment

Spinal Cord Injury Assessment by Product Type
Spinal Cord Injury By Stage and Product Type
Spinal Cord Injury Assessment by Route of Administration
Spinal Cord Injury By Stage and Route of Administration
Spinal Cord Injury Assessment by Molecule Type
Spinal Cord Injury by Stage and Molecule Type

DelveInsight's Spinal Cord Injury Report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Spinal Cord Injury product details are provided in the report. Download the Spinal Cord Injury pipeline report to learn more about the emerging Spinal Cord Injury therapies

Some of the key companies in the Spinal Cord Injury Therapeutics Market include:

Key companies developing therapies for Spinal Cord Injury are - NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others.

Spinal Cord Injury Pipeline Analysis:

The Spinal Cord Injury pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Cord Injury with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Cord Injury Treatment.
Spinal Cord Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Spinal Cord Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Cord Injury market.

Download Sample PDF Report to know more about Spinal Cord Injury drugs and therapies

Spinal Cord Injury Pipeline Market Drivers

Increase in prevalence of spinal cord injury, increasing awareness about the spinal cord injury are some of the important factors that are fueling the Spinal Cord Injury Market.

Spinal Cord Injury Pipeline Market Barriers

However, absence of essential emergency and acute care, lack of importance of a systematic approach towards the management of Spinal cord Injury and other factors are creating obstacles in the Spinal Cord Injury Market growth.

Scope of Spinal Cord Injury Pipeline Drug Insight

Coverage: Global
Key Spinal Cord Injury Companies: Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, NervGen Pharma, StemCyte, Inc., and others
Key Spinal Cord Injury Therapies: Allogeneic stem cell therapy, OLT1177, ALMB0166, AXER-204, FAB117-HC, AST-OPC1, Elezanumab, MT 3921, PMZ-1620, ES 135, KP-100IT, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, and others
Spinal Cord Injury Therapeutic Assessment: Spinal Cord Injury current marketed and Spinal Cord Injury emerging therapies
Spinal Cord Injury Market Dynamics: Spinal Cord Injury market drivers and Spinal Cord Injury market barriers

Request for Sample PDF Report for Spinal Cord Injury Pipeline Assessment and clinical trials

Table of Contents

1. Spinal Cord Injury Report Introduction

2. Spinal Cord Injury Executive Summary

3. Spinal Cord Injury Overview

4. Spinal Cord Injury- Analytical Perspective In-depth Commercial Assessment

5. Spinal Cord Injury Pipeline Therapeutics

6. Spinal Cord Injury Late Stage Products (Phase II/III)

7. Spinal Cord Injury Mid Stage Products (Phase II)

8. Spinal Cord Injury Early Stage Products (Phase I)

9. Spinal Cord Injury Preclinical Stage Products

10. Spinal Cord Injury Therapeutics Assessment

11. Spinal Cord Injury Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Spinal Cord Injury Key Companies

14. Spinal Cord Injury Key Products

15. Spinal Cord Injury Unmet Needs

16 . Spinal Cord Injury Market Drivers and Barriers

17. Spinal Cord Injury Future Perspectives and Conclusion

18. Spinal Cord Injury Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight